Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis

Abstract

Introduction Corticosteroid-induced osteoporosis (CIO) is the most common type of secondary osteoporosis, leading to fractures, and increased morbidity and mortality. Source of data Pubmed, EMBASE, Scopus and Google Scholar databases. Areas of agreement Prolonged glucocorticoids administration leads to secondary osteoporosis. Areas of controversy The optimal management for CIO is controversial. Growing points The present study compared bone mineral density, fractures and adverse events in patients undergoing treatment with risedronate, alendronate, zoledronate, denosumab or etidronate for CIO. Areas timely for developing research For selected patients with CIO, alendronate performed better overall. These results must be interpreted within the limitations of the present study. Level of evidence I, Bayesian network meta-analysis of randomized clinical trials.

Study on the treatment of postmenopausal osteoporosis with quercetin in Liuwei Dihuang Pill based on network pharmacology

“…According to Bayesian network meta-analysis, we found that corticosteroids, denosumab, Ibandronate, etc., can be effective drugs for the treatment of osteoporosis [ 20 , 21 ]. However, these drugs have their limitations, leading to secondary osteoporosis, etc.…”

Characteristics of subsequent contralateral proximal femoral fracture: more convenient access is needed to treat osteoporosis

“…The distributions of the start times of calcium and vitamin D supplementation, anti-osteoporosis medications, and dual X-ray absorptiometry (DXA) scanning relative to the initial and subsequent contralateral PFF were recorded through telephone or outpatient service. Anti-osteoporosis medications approved by the U.S. Food and Drug Administration at the time of this study included mainly bisphosphonates, teriparatide, denosumab, raloxifene, and calcitonin [ 15 , 16 ]. The start time was classified as < 2 years before the initial PFF, between the initial PFF and contralateral PFF, < 1 year after the contralateral PFF, or never (the “never” category included > 2 years before the initial fracture and > 1 year after the contralateral hip fracture).…”

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis

“…Alendronate, commonly applied in corticosteroid-induced osteoporosis treatment, is the cheapest and does not require subcutaneous administration. However, atypical femoral fractures (i.e., subtrochanteric fractures and focal lateral cortical thickening) and osteonecrosis of the jaw are two rare but severe side effects [15,38]. Another antiresorptive drug, denosumab, is a fully human monoclonal antibody to the receptor activator of nuclear factor-kappa B ligand, which could decrease bone resorption and increase bone density.…”